serval:BIB_A93C669EA17D
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
10.1007/s00018-012-0989-2
000308966200004
22527721
Ludigs
K.
author
Parfenov
V.
author
Du Pasquier
R.A.
author
Guarda
G.
author
article
review
2012
Cellular and Molecular Life Sciences
1420-9071
1420-682X
journal
69
20
3395-3418
Although contributing to inflammatory responses and to the development of certain autoimmune pathologies, type I interferons (IFNs) are used for the treatment of viral, malignant, and even inflammatory diseases. Interleukin-1 (IL-1) is a strongly pyrogenic cytokine and its importance in the development of several inflammatory diseases is clearly established. While the therapeutic use of IL-1 blocking agents is particularly successful in the treatment of innate-driven inflammatory disorders, IFN treatment has mostly been appreciated in the management of multiple sclerosis. Interestingly, type I IFNs exert multifaceted immunomodulatory effects, including the reduction of IL-1 production, an outcome that could contribute to its efficacy in the treatment of inflammatory diseases. In this review, we summarize the current knowledge on IL-1 and IFN effects in different inflammatory disorders, the influence of IFNs on IL-1 production, and discuss possible therapeutic avenues based on these observations.
Animals
Humans
Inflammation/drug therapy
Inflammation/metabolism
Interferon Type I/therapeutic use
Interleukin-1/metabolism
eng
60_published
true
peer-reviewed
University of Lausanne
mailto:serval_help@unil.ch
http://www.unil.ch/serval
http://serval.unil.ch/disclaimer
https://serval.unil.ch/notice/serval:BIB_A93C669EA17D